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Chronic Obstructive Pulmonary Disease (COPD) is a complex pathological condition associated with an important reduction
in physical activity and psychological problems that contribute to the patient’s disability and poor health-related quality of life.
Pulmonary rehabilitation is aimed to eliminate or at least attenuate these diﬃculties, mainly by promotingmuscular reconditioning.
e scope of this paper has been the analysis of the literature on pulmonary rehabilitation in COPD patients has appeared in the last
�ve years, focusing on the principal outcomes obtained.e results demonstrate that pulmonary rehabilitation has a bene�cial eﬀect
on dyspnoea relief, improving muscle strength and endurance. Moreover, pulmonary rehabilitation appears to be a highly eﬀective
and safe treatment for reducing hospital admissions mortality and improving health-related quality of life in COPD patients. It
represents, therefore, a very important therapeutic option that, alongwith standard pharmachological therapy, can be used to obtain
the best patientmanagement.e favourable results obtainedwith pulmonary rehabilitation programs should stimulate researchers
to improve our understanding of the mechanisms that form the basis of the bene�cial eﬀects of this therapeutic intervention. is
would in turn increase the eﬀectiveness of pulmonary rehabilitation in COPD patients.
1. Introduction
Pulmonary rehabilitation is de�ned by the American o-
racic Society and the European Respiratory Society as
an “evidence-based, multidisciplinary, and comprehensive
intervention for patients with chronic respiratory diseases
who are symptomatic and oen have decreased daily life
activities.” As such it is an integral part of the clinical manage-
ment and health maintenance of those patients with chronic
respiratory disease who remain symptomatic or continue
to have decreased lung function despite standard medical
treatment. Integrated into the individualised treatment of
the patient, pulmonary rehabilitation is designed to reduce
symptoms, optimise functional status, increase participation,
and reduce health care costs by stabilising or reversing
systemic manifestations of the disease [1]. All together these
considerations underline the general implications and the
importance of this respiratory treatment, which should be
considered fundamental during the management of chronic
obstructive pulmonary disease (COPD). In the last few years,
medical literature has provided evidence that pulmonary
rehabilitation favourably aﬀects outcomes in COPD [2]. In
spite of these important achievements, there is a need of
further improvements in pulmonary rehabilitation programs,
because COPD is still a major cause of disability worldwide,
besides mortality [3].
COPD is characterised by complex and diverse patho-
physiologic manifestations. e in�ammatory pulmonary
process, principally triggered by cigarette smoke, induces a
series of molecular and cellular reactions with detrimental
eﬀects on lung tissue [4]. e main and more important
manifestations of respiratory relevance are expiratory �ow
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limitation with dynamic collapse of the airways, air trapping,
and lung hyperin�ation [5]. e increase in respiratory rate
that occurs during exercise further ampli�es lung hyperin�a-
tion, leading to or worsening the “dynamic hyperin�ation”
due to tidal expiratory �ow limitation. �arious bronchodila-
tor drugs have proven able to improve pulmonary function,
promoting reduction of lung hyperin�ation at rest and
during exercise: thus, acute administration of tiotropium or
budesonide/formoterol increased inspiratory capacity and
decreased intrathoracic gas volume by about 0.4 L in 20
COPD patients [6]. Helium-oxygen mixtures (heliox) are
also being used to reduce lung hyperin�ation in COPD
patients on the assumption that if turbulent �ow occurs
during tidal breathing, a less dense gas mixture would reduce
airway resistance and prevent expiratory �ow limitation.
However, heliox did not abolish expiratory �ow limitation
in 26 stable COPD patients but reduced exercise dynamic
hyperin�ation in 25% of the patients and decreased exercise
dyspnoea in all of them [7]. is decrease was largely inde-
pendent of changes in dynamic hyperin�ation and tentatively
related to the fall of inspiratory resistance which follows
the reduction of turbulent �ow in the upper airways with
heliox.
In spite of the patient’s attempt to adopt more con-
venient breathing patterns, these adaptations are generally
overwhelmed during exercise, when there is an acute increase
in the ventilatory demand. Acute and chronic hyperin�a-
tion have been shown to contribute to exertional dysp-
noea, reduced ventilatory capacity, and worsened exercise
performance in COPD [8, 9]. Wasted ventilation further
increases the already high ventilatory demand requested for
the maintenance of blood gas homeostasis.
Although the initial pathology of COPD is con�ned
to the lung, the reduction in physical activity and psycho-
logical problems associated to the progress of the disease
increasingly contribute to the patient’s disability and poor
health-related quality of life. is forms the basis of the
most important clinical manifestations of COPD, such as
muscle dysfunction, cardiac impairment, skeletal and sensory
de�cits, malnutrition, and steroid-related myopathy [10],
besides respiratory muscle fatigue, sleep disorders, and psy-
chological alterations such as anxiety, depression, sense of
guilt, and carer dependency. e importance of the psycho-
logical pro�le has been clearly demonstrated, particularly
as far as anxiety and depression are concerned, both being
common occurrence in COPD patients, even when their
disease ismild in terms of respiratory function and symptoms
[11]. Indeed, depression has a prevalence rate of about 45%
in patients with moderate to severe COPD [12]. Hence, care
should be taken to design an adequate psychological and
social support within the pulmonary rehabilitation settings.
Exercise training is an important aspect of pulmonary
rehabilitation, as it represents the best available means of
improving muscle performance, with remarkable favourable
impact on exertional dyspnoea, exercise tolerance, and
improvement of daily activities [1]. Traditionally pulmonary
rehabilitation has focused on lower extremity training, little
or no attention being paid to training of upper limb muscles,
although they are regularly involved in all daily activities.e
minimum duration of exercise training in pulmonary reha-
bilitation has not been extensively investigated; however, the
ERS/ATS Statement suggests 20 sessions of a comprehensive
treatment as the best option.
Education of the patient is a core component of a com-
plete rehabilitation program, together with the prevention
and early treatment of respiratory exacerbations, implemen-
tation of breathing strategies, and bronchial cleaning. e
combination of postural drainage, percussion, and forced
expiration improve airway clearance, while the use of a
positive expiratory pressuremask and assisted coughing have
proven to be more eﬀective than assisted coughing alone in
COPD patients during an exacerbation [13]. In fact, for some
patients mucus hypersecretion and impaired mucociliary
transport represent distinctive features of their lung disease,
and for these reasons they require particular and appropriate
instructions.
Pulmonary rehabilitation programs should also address
body composition abnormalities, which are frequently
present but underrecognised in chronic lung diseases. Inter-
ventions relating to these aspectsmay be in the formof caloric
supplementation, physiological interventions, pharmacolog-
ical strategies, or combination therapy in order to induce
weight gain without an overall fat mass increase. All of these
interventions have resulted in an improvement in quality of
life and justify the decision taken by oﬃcial organisations to
recommend pulmonary rehabilitation as an integral part of
the long-term management of COPD [14–17].
While the utility of pulmonary rehabilitation is undis-
puted, no general consensus exists regarding the parame-
ters that should best represent the improvements achieved
with pulmonary rehabilitation. Indeed, the various research
groups have focused on diﬀerent parameters, like exercise
performance, endurance, dyspnoea, and quality of life, while
little or no attention have been paid to a number of parame-
ters concerned with respiratory mechanics and gas exchange.
e absence of homogeneity regarding the study endpoints
largely limits the comparison among the various studies,
besides evaluation of their results. With this in mind, we have
analysed the literature on pulmonary rehabilitation in COPD
patients that has appeared in the last �ve years, focusing on
the main outcomes used and their evaluation.
2. Selection Criteria
We conducted a MEDLINE search using the keywords
“pulmonary rehabilitation” and “COPD”: of the resulting
1294 articles, 574 had been published in the last �ve years, but
only 398 had pulmonary rehabilitation as the relevant issue.
ese papers could be classi�ed as follows: 121 clinical trials,
78 randomised clinical trials, 10 meta-analyses, 4 practical
guide lines, 131 reviews, and 54 systematic reviews (Figure
1). Guide lines and reviews were discarded. Among clinical
trials, we took into consideration those that were performed
following a randomisation design and those which included
a representative number of patients (>200). Two additional
studies involving a smaller number of patients were included













F 1: Distribution of scienti�c literature about pulmonary
rehabilitation.
in an out-patient pulmonary rehabilitation program [18], the
other because it deals with a new approach, namely, the home
exercise video program [19]. With these restrictions, only 19
papers could be taken into consideration (Table 1).
3. Results
In all studies, the duration of the pulmonary rehabilitation
programs was six-to-twelve weeks. Furthermore, all pro-
grams were based on a multidisciplinary approach: exercise
training, patient education, psychosocial and behavioural
interventions, and nutritional therapy to contrast weight
loss and muscle wasting. It is important to underline that
only three papers made the distinction between primary
and secondary outcomes. Furthermore, two of them have
evaluated the improvement of the quality of life aer the
Saint George Respiratory Questionnaire (SGRQ) score as the
primary outcome [20, 21], whereas the third one has used the
Chronic Respiratory Disease Questionnaire (CRQ) [22].
e conclusion common to all papers listed in Table
1 is that pulmonary rehabilitation improves the 6MWTD,
maximal oxygen consumption, treadmill endurance time,
exertional and overall dyspnoea, and self-eﬃcacy forwalking,
in line with studies performed in the 90s [37–39]. Brie�y,
the assessment of pulmonary rehabilitation has been made
according to three perspectives: functional outcomes, dysp-
noea perception, and quality of life.
3.1. Functional Outcomes. Twelve studies have analysed the
six-minute walking test distance (6MWTD) as a functional
parameter; all of them concluded that pulmonary rehabili-
tation of COPD patients leads to an increase of the covered
distance. Nine of those papers also evaluated other variables
such as the incremental shuttle test, leg strength, and the peak
oxygen intake and found that they were correlated with the
6MWTD. Moreover, in a retrospective analysis involving a
cohort of 815 severe or very severe COPD patients undergo-
ing a pulmonary rehabilitation program based on increasing
exercise tolerance, transfers, and stair climbing, En�eld et al.
[28] found that the 6min walking distance was increased by
an average 90metres and that these changes were positively
associated with the increase of survival rate. erefore, the
6MWTD appears to be an important, simple, and repeatable
parameter to evaluate the functional improvement obtained
with a pulmonary rehabilitation program, independent of the
severity of the disease.
Only 3 studies have considered Forced Expiratory Volume
in t�e �rst second (FEV1) as a functional parameter. Stav et
al. [31] reported a consistent reduction of the rate of FEV1
decline or even a suppression of that decline aer three years
of pulmonary rehabilitation, while Ergün et al. [18] and
Chang et al. [20] found no signi�cant changes in FEV1 aer
8 weeks of pulmonary rehabilitation.
3.2. Dyspnoea Perception. Four studies evaluated dyspnoea
using the MRC or Borg scale. Ergün et al. [18] demonstrated
a decrease in dyspnoea sensation by an average of 1.2 units
of the MRC scale, both in the early and the late-stage group
of COPD patients. Similarly, no signi�cant diﬀerences in
dyspnoea score were observed between those two groups in
a randomized, controlled, prospective study on 78 COPD
patients aiming to assess the eﬀectiveness of a pulmonary
rehabilitation program performed in a community hospital
[34]. On the contrary, Scott et al. [30], using the Borg scale
to assess dyspnoea severity in a prospective, observational
study, concluded that patients with higher baseline FEV1
were more likely to enjoy an attenuation of breathlessness,
besides greater improvement of both subjective (SGRQ) and
objective outcomes (6MWD).
Few data are available concerning the eﬀectiveness of
pulmonary rehabilitation on dyspnoea relief in less severe
COPD patients. In a 2-year randomised controlled trial on
patients with moderate air�ow obstruction but impaired
exercise capacity, it was found that a signi�cantly greater
decrease of MRC dyspnoea score from baseline occurred in
the group of patients subjected to active treatment [21].
3.3. Quality of Life. Ten studies have evaluated the improve-
ments in quality of life using either the SGRQ, CRQ, or
Hospital Anxiety Depression (HADs) scale. Van Wetering
et al. [21] have conducted a 2-year randomised controlled
trial in which the eﬃcacy of the conventional treatments was
compared with that of a newly designed Interdisciplinary
Community-based (INTERCOM) COPD management pro-
gram, consisting in a 4-month rehabilitation phase and a
20-month active maintenance phase. e primary outcomes
were the change from baseline in disease-speci�c quality
of life as assessed by the SGRQ total score and the total
number of exacerbations. At 12 months, the SGRQ score
in the INTERCOM group had almost returned to baseline,
whereas in the conventional care group it remained stable up
to 12months andworsened thereaer.e authors concluded
that INTERCOMproved to be a feasible approach to improve
disease-speci�c quality of life, dyspnoea, and functional
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T 1: Selected studies for the review and used outcomes.
Main author/year Type of study Outcomes
van Ranst et al. 2011 [23] Retrospective,observational
(i) Peripheral muscle performance
(ii) Respiratory muscle strength
(iii) Cycle exercise endurance and 6MWDT
(iv) CRQ, SGRQ, SF-36
Yoshimi et al. 2012 [24] Prospective, observational
(i) Respiratory muscle strength
(ii) 6MWDT
(iii) SGRQ
Murphy et al. 2011 [22] Single-blind clusterrandomised trial
(i) 1∘: CRQ
(ii) 2∘: ISWT, Self-eﬃcacy for Managing Chronic Disease 6-Item Scale
Fischer et al. 2012 [25] Prospective, observational (i) 6MWDT(ii) Correlation between concerns about exercise and 6MWDT
Gale et al. 2011 [26] Prospective cohort study (i) PWV, BP, IL-6, fasting glucose and lipids(ii) ISWT
Riario-Sforza et al. 2009
[27]
Number needed to treat
study 6MWDT
En�eld et al. 2010 [28] Retrospective,observational cohort study Relationship between 6MWD and survival
Cheikh Rejbi et al. 2010
[29] Prospective, observational 6MWDT and peak oxygen uptake in COPD and healthy subjects
Ergün et al. 2011 [18] Prospective, observational
(i) MRC, BORG dyspnea scale
(ii) ISWT, ESWT, FEV1
(iii) SGRQ, HADs
(iv) Body composition: BMI, FFM




(iv) BORG dyspnea scale




Moore et al. 2009 [19] Randomised pilot study (i) ISWT(ii) CRQ
Steele et al. 2008 [32] Randomised clinical trial
(i) Daily activity with accelerometer
(ii) Exercise adherence with diary
(iii) 6MWDT
Eaton et al. 2009 [33] Prospective randomizedcontrolled study Risk of readmission at 3months aer an exacerbation
Chang et al. 2008 [20] ree-group randomisedcontrolled trial
(i) 1∘: SGRQ
(ii) 2∘: FAI, IPAQ, ISWT, FEV1










(i) 1∘: SGRQ, n ∘ of exacerbations
(ii) 2∘: subscores of SGRQ, MRC, 6MWDT, muscle strength, FFM, lung
function







Sabit et al. 2008 [36] Retrospective case notestudy Identifying variables that aﬀect poor attendance to PR programme
6MWDT: 6-minute walking distance test, CRQ: chronic respiratory disease questionnaire, SGRQ: St George’s respiratory questionnaire, SF-36: medical
outcomes study short-form survey, PWV: aortic pulse wave velocity, BP: blood pressure, IL-6: interleukin-6, ISWT: incremental shuttle walk test, ESWT:
endurance shuttle walking test, HADs: hospital anxiety depression scale, BMI: body mass index, FFM: fat free mass, FEV1: forced expiratory volume in one
second, FAI: Frenchay activities index, IPAQ: international physical activity questionnaire.
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exercise capacity. On the other hand, the frequency of
exacerbations was not signi�cantly diﬀerent between the
groups during the 2-year period of observation. e other
two studies that used quality of life as primary outcome
also concluded that pulmonary rehabilitation is eﬀective in
improving the health-related quality of life in COPD patients
[20, 22], and a similar conclusion was reached in the studies
that have used quality of life as an additional or secondary
outcome [18, 19, 23, 24, 30, 34, 35].
It should be stressed, however, that these studies were
carried out on patients with a stable disease, while it is well
known that exacerbations are an important and negative
prognostic element in the natural history of the disease [40],
becoming more frequent as the disease progresses [41]. is
should be taken into account for a comprehensive evaluation
of the impact of pulmonary rehabilitation programs. Indeed,
randomised controlled trials performed over a 2-year period
have shown that pulmonary rehabilitation has no impact
on incidence of exacerbations and health-care utilization,
although there were improvements in disease-speci�c quality
of life, dyspnoea scores, and exercise capacity [21, 33].
4. Discussion
e purpose of this paper has been to analyse the out-
comes used in studies on pulmonary rehabilitation in COPD
patients published over the last �ve years, besides the e�cacy
of these treatments in improving the quality of life and the
ability in carrying out daily life activities. Almost all studies
have assumed as a primary outcome for the evaluation of
the pulmonary rehabilitation programs the distance covered
during the six-minute walking test and the peripheral muscle
strength, with less attention paid to the impact on the quality
of life.
A growing amount of literature advocates home-based
rehabilitation as a useful adjunct for COPD management
[42, 43]. Home-based interventions are a cheaper, more
cost-eﬀective method of care than traditional hospital treat-
ment [44–46] and enable patients to remain in their own
environments, close to the family, where exercise training
speci�c to their daily activities can be applied [42, 47, 48]. It
must be noted, however, that home-based interventions are
principally focused on respiratory muscle training, whereas
pulmonary rehabilitation performed in the hospital tackles
additional aspects, such as quality of life, breathlessness
sensation, psychological pro�le, and eﬀectiveness of thera-
peutic interventions [49]. Furthermore, hospital-based, mul-
tidisciplinary pulmonary rehabilitation programs include
interventions that promote airway clearance, as accumulation
of secretions in COPD contributes substantially to airway
obstruction. Application of positive end-expiratory pressure
has been shown very eﬀective to remove bronchial secretions
and reduce atelectasis. It is also the most eﬀective treatment
available in reducing the need for increased ventilatory
assistance and duration of hospital stay aer an exacerbation
[50], while concomitant bronchodilation therapy can also
help mobilisation of secretions, as it positively aﬀects the
ciliary beat frequency of respiratory epithelium [51]. Further-
more, several studies have investigated the nonadherence to
inhalatory medications of COPD patients; it has been in fact
reported that to 18% of patients spontaneously discontinue
the respiratory therapy [52], and it is reasonable to suppose
that the incidence would be greater in patients involved in
a home-based rehabilitation program. On the other hand,
there is a paucity of data regarding the adherence in attending
pulmonary rehabilitation programs. In a retrospective anal-
ysis, Sabit et al. [36] have concluded that COPD patients are
less likely to complete a pulmonary rehabilitation program
if they are current smokers, attend a long lasting program,
suﬀer frequent exacerbations requiring hospital admission,
and have higher MRC score. ere is therefore the need
for a worldwide multicentre investigation to better under-
stand what kind of COPD patients should be assigned to
pulmonary rehabilitation programs, also in connection with
the available resources.
Of particular interest is the hypothesis that pulmonary
rehabilitation, through the exercise and nutritional interven-
tion, could reduce the risk of cardiovascular accidents [26],
because it is well known that patients with COPD have an
increased risk of cardiovascular disease. e hypothesis was
supported by the observation that following rehabilitation,
the aortic pulse wave velocity (PWV) was reduced together
with a marked fall in systemic blood pressure [26]. Moreover,
there was a modest reduction in total cholesterol. is study,
the �rst that evaluates the eﬀect of a standardised multidisci-
plinary pulmonary rehabilitation program on cardiovascular
risk factors in patients with COPD, indicates that pulmonary
rehabilitation could represent an opportunity to identify
and treat cardiovascular and metabolic dysfunction in these
patients, thus providing additional bene�ts.
e primary goal of pulmonary rehabilitation should be,
however, the improvement of lung mechanics, in order to
lower the work of breathing and restore ventilation-perfusion
distribution, with enhanced gas exchange and exercise per-
formance. ese pathogenetic cornerstones of COPD should
be treated both with pharmacological bronchodilation and
pulmonary rehabilitation, in order to reduce respiratory
symptoms in stable patients and during exacerbations [51,
53]. ere are, in fact, clear indications for performing
pulmonary rehabilitation aer acute exacerbations in COPD
patients, besides conventional community care, as this treat-
ment appears to be safe and highly eﬀective in reducing
hospital admissions and mortality and in improving health-
related quality of life [54].
5. Conclusion
Current literature supports the notion that pulmonary reha-
bilitation provides clinically relevant improvements in quality
of life, breathlessness, exercise performance, and psycholog-
ical status. Also the usefulness of the association of conven-
tional pharmacological treatment and pulmonary rehabilita-
tion has been repeatedly proven [49]. However, uncertainties
remain regarding some elements of pulmonary rehabilitation
programs, such as duration and yearly frequency of the
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cycles, training intensity, and degree of supervision, for
which further investigations are required. Furthermore, the
present analysis has shown that only very few studies have
considered pulmonary function parameters among expected
outcomes. is, together with lack of assessment of absolute
lung volume partitioning and tidal expiratory �ow limitation,
largely prevents the possibility to better understand the eﬀects
of pulmonary rehabilitation on the respiratory system, urging
for further studies in this area.
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